Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,414 across all filing types
Latest filing 2025-01-21 Regulatory Filings
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Press Release: Opella reaches study milestone for Cialis
Regulatory Filings Classification · 100% confidence The document is explicitly titled '# **Press Release**' and contains announcements regarding a clinical study milestone for Cialis, quotes from executives, and standard boilerplate sections like 'About Cialis', media contacts, and 'forward-looking statements'. This format is characteristic of an initial announcement of significant business or operational news, rather than a comprehensive financial report (10-K, IR) or a transcript (CT). Since it is an initial announcement of results/developments, the most appropriate classification among the options is 'Earnings Release' (ER), although this document is about a regulatory/clinical milestone rather than financial earnings. However, given the options, 'ER' often serves as the general category for initial press releases announcing key operational updates, especially when a more specific category like 'LTR' (Legal Proceedings Report) or 'CAP' (Capital/Financing Update) does not fit. Since this is a press release announcing a significant regulatory/clinical event, and it is not a formal regulatory filing like a 10-K or a short announcement of a report (RPA/RNS), 'ER' is the closest fit for a general operational update press release. If 'Press Release' were an option, it would be chosen. Given the constraints, and recognizing it's a primary announcement, ER is selected, though RNS (Regulatory Filings) is also a possibility if the focus is purely on the FDA interaction. Given the structure and content (executive quotes, product focus), ER is slightly favored over the generic RNS.
2025-01-21 English
Sanofi: Information concerning the total number of voting rights and shares – November 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly states it concerns 'Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce... and article 223-16 of the Règlement général de l'Autorité des Marchés Financiers'. It provides a table detailing the total number of issued shares and voting rights as of a specific date (October 31, 2024). This type of mandatory disclosure regarding the total share capital and voting power structure is a specific regulatory filing requirement, often related to capital structure updates or general shareholder information, but it is not a full report (10-K, IR), an earnings release (ER), or a dividend notice (DIV). It is a specific regulatory disclosure about the share count. Among the provided codes, 'SHA' (Share Issue/Capital Change) is the closest fit as it deals directly with the number of shares and voting rights, which are fundamental components of the capital structure. It is a direct regulatory disclosure, not an announcement of a report (RPA/RNS).
2025-01-15 English
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Novembre 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Informations relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du Code de commerce et l'article 223-16 du Règlement général de l'Autorité des Marchés Financiers'. It provides a table detailing the total number of shares and voting rights as of a specific date (November 30, 2024), referencing French regulatory articles (Code de commerce and AMF General Regulation). This type of mandatory disclosure regarding the total number of voting rights is a specific regulatory filing requirement, often related to capital structure transparency. It is not a full annual report (10-K), an earnings release (ER), or a general management/board change announcement (MANG). While it relates to capital structure, it is a specific regulatory disclosure about voting rights rather than a financing event (CAP) or a general share transaction (POS/SHA). Given the specific nature of reporting total voting rights as mandated by financial authorities, it fits best under the general 'Regulatory Filings' (RNS) category as a specific, recurring regulatory disclosure that doesn't match the other specialized codes, although it is highly specific. However, since it is a direct, mandatory disclosure of share/voting rights information, it is closely related to capital structure reporting. Reviewing the definitions, none perfectly capture 'Total Voting Rights Disclosure'. It is a regulatory filing, making RNS a strong candidate. If we consider the closest fit among the options, it is a specific regulatory disclosure about the capital base, but RNS is the designated fallback for specific regulatory announcements not covered elsewhere. Given the context of French AMF regulations, this is a standard, periodic disclosure. I will classify it as RNS (Regulatory Filings) as the most appropriate general regulatory category.
2025-01-15 French
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC under the Securities Exchange Act of 1934. It includes references to press releases attached as exhibits, which are typical for 6-K filings. The document length is short (1550 characters), and it primarily serves as a regulatory filing to disclose recent press releases and updates. There is no detailed financial data, management discussion, or full report content. According to the rules, such filings are classified as Regulatory Filings (RNS) because they do not contain full reports or substantive financial data but are regulatory announcements.
2025-01-14 English
Communiqué de presse : Sarclisa : première approbation en Chine pour le traitement du myélome multiple en rechute ou réfractaire de l’adulte
Regulatory Filings Classification · 95% confidence The document is titled "Communiqué de presse" (Press Release) and announces a specific regulatory event: the approval of the drug Sarclisa by the Chinese National Medical Products Administration (NMPA) for treating multiple myeloma. It details the clinical studies (ICARIA-MM, IsaFiRsT) that supported this approval and includes forward-looking statements typical of corporate news releases regarding future regulatory decisions (e.g., VRd application). This content structure—a formal announcement of a significant business/regulatory event, often released to the public before formal SEC/exchange filings—is characteristic of a general corporate announcement or press release. Since there is no specific category for a 'Press Release' that isn't an earnings release (ER) or a specific regulatory filing (like 10-K or DIV), and it is not primarily focused on management changes (MANG), director dealings (DIRS), or dividend notices (DIV), the most appropriate general category for a significant, non-standardized corporate announcement is 'Regulatory Filings' (RNS), as it covers miscellaneous filings that do not fit neatly elsewhere, or potentially an 'Earnings Release' (ER) if this were tied to a financial period, but it is clearly a product approval announcement. Given the focus on regulatory approval and clinical data dissemination via a press release format, RNS is the best fit as a catch-all for significant, non-periodic corporate news that isn't explicitly defined elsewhere. It is not an ER because it is not reporting financial results.
2025-01-13 French
Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma
Regulatory Filings Classification · 100% confidence The document is explicitly titled "Press Release" and announces a significant corporate event: the first approval in China for the drug Sarclisa by the National Medical Products Administration (NMPA). It contains key financial/operational highlights, quotes from management, details about clinical studies (ICARIA-MM, IsaFiRsT), and standard forward-looking statements typical of a public announcement intended for immediate dissemination to the market and media. This structure strongly indicates an Earnings Release (ER) or a general announcement. Since it is focused on a regulatory/product milestone rather than periodic financial results (like quarterly revenue/net income), and it is a formal announcement, it fits best as a general announcement or a specific regulatory/operational update. Given the options, it is a high-impact announcement that is not a formal financial report (10-K, IR) or a transcript (CT). It is most closely aligned with an Earnings Release (ER) in terms of format (Press Release announcing key news) or potentially a Regulatory Filing (RNS) if it were less detailed. However, because it is a detailed announcement of a major business event (drug approval) with management commentary, it functions similarly to an ER announcing operational success, but since 'ER' is defined as 'Initial announcement of quarterly/periodical financial results (key highlights only)', and this is a product/regulatory milestone, the most appropriate general category for a significant, non-periodic, non-statutory announcement that doesn't fit elsewhere is often RNS, or if it's a major operational update, it might be considered a type of ER substitute. Given the context of a major drug approval announcement, which is critical operational news, and the lack of a specific 'Product Approval Announcement' category, I will classify it as a general Regulatory Filing (RNS) as it is a formal announcement to the market regarding regulatory action, or potentially ER if we interpret 'key highlights' broadly. Since it is a press release announcing regulatory success, RNS is the safest fallback for non-standard filings. However, many companies issue press releases for major operational milestones that function like ERs. Given the structure and purpose (announcing a major milestone), and recognizing that RNS is the fallback, I will check if it fits ER better. ER is for financial results. This is a regulatory/product success. Therefore, RNS (Regulatory Filings - general regulatory announcements and fallback) is the most appropriate fit for a non-financial, non-meeting related, non-insider trade announcement.
2025-01-13 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.